IgG Structure and Function

Encyclopedia of Immunobiology

Volumn 2, Issue , 2016, Pages 15-22

  Thomson, Christy A ^a  

^a Amgen British Columbia Inc   (Canada)

Author keywords

Antibody; Antigen; Complement; Constant domain; Effector function; Fc R; Glycoprotein; Humoral immunity; Immunoglobulin fold; Subclass; Variable domain

Indexed keywords

EID: 84957711865     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374279-7.05002-5     Document Type: Chapter

References (71)

1. Ahmed A.A., Giddens J., Pincetic A., Lomino J.V., Ravetch J.V., Wang L.X., Bjorkman P.J. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J. Mol. Biol. 2014, 426:3166-3179.
2. Al-Lazikani B., Lesk A.M., Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 1997, 273:927-948.
3. H fusions. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:4118-4122.
4. Alzari P.M., Lascombe M.B., Poljak R.J. Three-dimensional structure of antibodies. Annu. Rev. Immunol. 1988, 6:555-580.
5. Amzel L.M., Poljak R.J. Three-dimensional structure of immunoglobulins. Annu. Rev. Biochem. 1979, 48:961-997.
6. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
7. Brambell F.W. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 1966, 2:1087-1093.
8. Bransteitter R., Pham P., Scharff M.D., Goodman M.F. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4102-4107.
9. Burnet F.M. A modification of Jerne's theory of antibody production using the concept of clonal selection. CA Cancer J. Clin. 1976, 26:119-121.
10. Butler J.E., Wertz N. Antibody repertoire development in fetal and neonatal piglets. XVII. IgG subclass transcription revisited with emphasis on new IgG3. J. Immunol. 2006, 177:5480-5489.
11. Butler J.E., Wertz N., Deschacht N., Kacskovics I. Porcine IgG: structure, genetics, and evolution. Immunogenetics 2009, 61:209-230.
12. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6:343-357.
13. Corcos D., Osborn M.J., Matheson L.S., Santos F., Zou X., Smith J.A., Morgan G., Hutchings A., Hamon M., Oxley D., Bruggemann M. Immunoglobulin aggregation leading to Russell body formation is prevented by the antibody light chain. Blood 2010, 115:282-288.
14. van Der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., Den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., Van De Winkel J.G., Aalberse R.C., Parren P.W. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
15. Desiderio S.V., Yancopoulos G.D., Paskind M., Thomas E., Boss M.A., Landau N., Alt F.W., Baltimore D. Insertion of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cells. Nature 1984, 311:752-755.
16. Diebolder C.A., Beurskens F.J., De Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M., Ugurlar D., Rosati S., Heck A.J., Van De Winkel J.G., Wilson I.A., Koster A.J., Taylor R.P., Saphire E.O., Burton D.R., Schuurman J., Gros P., Parren P.W. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014, 343:1260-1263.
17. Dillon T.M., Ricci M.S., Vezina C., Flynn G.C., Liu Y.D., Rehder D.S., Plant M., Henkle B., Li Y., Deechongkit S., Varnum B., Wypych J., Balland A., Bondarenko P.V. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J. Biol. Chem. 2008, 283:16206-16215.
18. Edelman G.M., Benacerraf B., Ovary Z., Poulik M.D. Structural differences among antibodies of different specificities. Proc. Natl. Acad. Sci. U.S.A. 1961, 47:1751-1758.
19. Ghirlando R., Lund J., Goodall M., Jefferis R. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol. Lett. 1999, 68:47-52.
20. Gillies S.D., Morrison S.L., Oi V.T., Tonegawa S. A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. Cell 1983, 33:717-728.
21. Hamilton R.G. Human IgG subclass measurements in the clinical laboratory. Clin. Chem. 1987, 33:1707-1725.
22. Harpaz Y., Chothia C. Many of the immunoglobulin superfamily domains in cell adhesion molecules and surface receptors belong to a new structural set which is close to that containing variable domains. J. Mol. Biol. 1994, 238:528-539.
23. Harris L.J., Larson S.B., Hasel K.W., Mcpherson A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 1997, 36:1581-1597.
24. Hassan M.S., Islam K.B., Hammarstrom L., Smith C.I. Regulation of C gamma 3 expression. Role of switch in the allotype-associated variation of human serum IgG3 levels. J. Immunol. 1992, 148:2555-2562.
25. He F., Hogan S., Latypov R.F., Narhi L.O., Razinkov V.I. High throughput thermostability screening of monoclonal antibody formulations. J. Pharm. Sci. 2010, 99:1707-1720.
26. Honegger A., Pluckthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J. Mol. Biol. 2001, 309:657-670.
27. Ionescu R.M., Vlasak J., Price C., Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J. Pharm. Sci. 2008, 97:1414-1426.
28. Ito T., Tsumoto K. Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress. Protein Sci. 2013, 22:1542-1551.
29. Johnson G., Wu T.T. Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res. 2000, 28:214-218.
30. Junghans R.P., Anderson C.L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:5512-5516.
31. Kabat E.A. Unique features of the variable regions of Bence Jones proteins and their possible relation to antibody complementarity. Proc. Natl. Acad. Sci. U.S.A. 1968, 59:613-619.
32. H genes. Cell 1981, 27:573-581.
33. Lang J., Jackson M., Teyton L., Brunmark A., Kane K., Nemazee D. B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. J. Exp. Med. 1996, 184:1685-1697.
34. Latypov R.F., Hogan S., Lau H., Gadgil H., Liu D. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J. Biol. Chem. 2012, 287:1381-1396.
35. Lederberg J. Genes and antibodies. Science 1959, 129:1649-1653.
36. Lefranc M.P. IMGT, the international ImMunoGeneTics database: a high-quality information system for comparative immunogenetics and immunology. Dev. Comp. Immunol. 2002, 26:697-705.
37. Lefranc M.P. Immunoinformatics of the V, C, and G domains: IMGT(R) definitive system for IG, TR and IgSF, MH, and MhSF. Methods Mol. Biol. 2014, 1184:59-107.
38. Liu M., Duke J.L., Richter D.J., Vinuesa C.G., Goodnow C.C., Kleinstein S.H., Schatz D.G. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008, 451:841-845.
39. Liu Z., Gunasekaran K., Wang W., Razinkov V., Sekirov L., Leng E., Sweet H., Foltz I., Howard M., Rousseau A.M., Kozlosky C., Fanslow W., Yan W. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J. Biol. Chem. 2014, 289:3571-3590.
40. Lux A., Nimmerjahn F. Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J. Clin. Immunol. 2013, 33(Suppl. 1):S4-S8.
41. Martinez T., Guo A., Allen M.J., Han M., Pace D., Jones J., Gillespie R., Ketchem R.R., Zhang Y., Balland A. Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry 2008, 47:7496-7508.
42. Nimmerjahn F., Gordan S., Lux A. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 2015, 36:325-336.
43. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
44. Nossal G.J., Lederberg J. Antibody production by single cells. Nature 1958, 181:1419-1420.
45. Oganesyan V., Gao C., Shirinian L., Wu H., Dall'Acqua W.F. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. Sect. D Biol. Crystallogr. 2008, 64:700-704.
46. Pauling L. A theory of the structure and process of formation of antibodies. J. Am. Chem. Soc. 1940, 62:2643-2657.
47. Poljak R.J., Amzel L.M., Avey H.P., Chen B.L., Phizackerley R.P., Saul F. Three-dimensional structure of the Fab fragment of a human immunoglobulin at 2.8-Å resolution. Proc. Natl. Acad. Sci. U.S.A. 1973, 70:3305-3310.
48. Porter R.R. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem. J. 1959, 73:119-126.
49. Qiao S.W., Kobayashi K., Johansen F.E., Sollid L.M., Andersen J.T., Milford E., Roopenian D.C., Lencer W.I., Blumberg R.S. Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9337-9342.
50. Rispens T., Leeuwen A., Vennegoor A., Killestein J., Aalberse R.C., Wolbink G.J., Aarden L.A. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal. Biochem. 2011, 411:271-276.
51. Rispens T., Ooijevaar-De Heer P., Bende O., Aalberse R.C. Mechanism of immunoglobulin G4 Fab-arm exchange. J. Am. Chem. Soc. 2011, 133:10302-10311.
52. Ryazantsev S., Tischenko V., Nguyen C., Abramov V., Zav'yalov V. Three-dimensional structure of the human myeloma IgG2. PLoS One 2013, 8:e64076.
53. Salfeld J.G. Isotype selection in antibody engineering. Nat. Biotechnol. 2007, 25:1369-1372.
54. Schiffer M., Girling R.L., Ely K.R., Edmundson A.B. Structure of a lambda-type Bence-Jones protein at 3.5-Å resolution. Biochemistry 1973, 12:4620-4631.
55. Shields R.L., Lai J., Keck R., O'connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277:26733-26740.
56. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., Presta L.G. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001, 276:6591-6604.
57. Spiekermann G.M., Finn P.W., Ward E.S., Dumont J., Dickinson B.L., Blumberg R.S., Lencer W.I. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med. 2002, 196:303-310.
58. Stoops J., Byrd S., Hasegawa H. Russell body inducing threshold depends on the variable domain sequences of individual human IgG clones and the cellular protein homeostasis. Biochim. Biophys. Acta 2012, 1823:1643-1657.
59. Talmage D.W. Immunological specificity, unique combinations of selected natural globulins provide an alternative to the classical concept. Science 1959, 129:1643-1648.
60. Thai T.H., Purugganan M.M., Roth D.B., Kearney J.F. Distinct and opposite diversifying activities of terminal transferase splice variants. Nat. Immunol. 2002, 3:457-462.
61. Thomson C.A., Bryson S., Mclean G.R., Creagh A.L., Pai E.F., Schrader J.W. Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J. 2008, 27:2592-2602.
62. Tiegs S.L., Russell D.M., Nemazee D. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 1993, 177:1009-1020.
63. Tonegawa S., Steinberg C., Dube S., Bernardini A. Evidence for somatic generation of antibody diversity. Proc. Natl. Acad. Sci. U.S.A. 1974, 71:4027-4031.
64. Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 2014, 5:520.
65. Vidarsson G., Stemerding A.M., Stapleton N.M., Spliethoff S.E., Janssen H., Rebers F.E., De Haas M., Van De Winkel J.G. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006, 108:3573-3579.
66. White A.L., Chan H.T., French R.R., Willoughby J., Mockridge C.I., Roghanian A., Penfold C.A., Booth S.G., Dodhy A., Polak M.E., Potter E.A., Ardern-Jones M.R., Verbeek J.S., Johnson P.W., Al-Shamkhani A., Cragg M.S., Beers S.A., Glennie M.J. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015, 27:138-148.
67. Wright A., Tao M.H., Kabat E.A., Morrison S.L. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J. 1991, 10:2717-2723.
68. Wu T.T., Kabat E.A. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 1970, 132:211-250.
69. Young E., Lock E., Ward D.G., Cook A., Harding S., Wallis G.L. Estimation of polyclonal IgG4 hybrids in normal human serum. Immunology 2014, 142:406-413.
70. Zhu K., Day T., Warshaviak D., Murrett C., Friesner R., Pearlman D. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction. Proteins 2014, 82:1646-1655.
71. - IMGT(c), the International Immunogenetics Information System. http://www.imgt.org/.